The utility of routine HEMAtological indices in prediction of ischemic and hemorrhagic events in patients after Percutaneous Coronary Intervention

The utility of routine HEMAtological indices in prediction of ischemic and hemorrhagic events in patients after Percutaneous Coronary Intervention - HemaPCI Registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020892

Enrollment

1492

Registered

2020-02-18

Start date

2020-02-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I25 I21

Interventions

Group 1: The research is an investigator-initiated, prospective, longitudinal, cohort observational study. Thus, observational groups will be defined according to values of obtained routine hematologi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: consecutive patients with diagnosis of different forms of coronary artery disease (ICD-10 code I20-25) treated with percutaneous coronary intervention.

Exclusion criteria

Exclusion criteria: 1. deny to provide informed consent 2. death during index hospital stay 3. absence of available CBC measurements 4. terminal chronic kidney disease requiring dialysis 5. end-stage liver insufficiency 6. cancer 7. hematological proliferative diseases 8. active infections with thrombocytopenia 9. pregnancy 10. age less than 18 years old 11. patients without active legal competence

Design outcomes

Primary

Measure	Time frame
1. Recurrent patient-oriented weighted composite endpoints with endpoint definitions proposed by the Academic Research Consortium-2 Consensus Document (doi: 10.1161/CIRCULATIONAHA.117.029289). The weights of the individual endpoints will be predefined according to the Delphi panel of experts (doi:10.1093/eurheartj/ehu262). 2. Recurrent composite endpoint of all-cause mortality, myocardial infarction and stroke with a joint frailty survival model.	—

Measure

Time frame

1. Recurrent patient-oriented weighted composite endpoints with endpoint definitions proposed by the Academic Research Consortium-2 Consensus Document (doi: 10.1161/CIRCULATIONAHA.117.029289). The weights of the individual endpoints will be predefined according to the Delphi panel of experts (doi:10.1093/eurheartj/ehu262). 2. Recurrent composite endpoint of all-cause mortality, myocardial infarction and stroke with a joint frailty survival model.

—

Secondary

Measure	Time frame
1. Recurrent device-oriented weighted composite endpoints with endpoint definitions proposed by the Academic Research Consortium-2 Consensus Document. The weights of the individual endpoints will be predefined according to the Delphi panel of experts (doi:10.1093/eurheartj/ehu262). 2. Recurrent individual components of aforementioned composite endpoints: all-cause mortality, cardiovascular death, stroke (as defined by an academic research consortium initiative – doi:10.1093/eurheartj/ehx037), myocardial infarction, any revascularization, target lesion revascularization. These endpoint will be analyzed in a joint frailty survival model. 3. Recurrent effectiveness endpoints as a composite of any coronary revascularization (clinically driven) and any hospitalization either for a cardiac reason or related to the procedure with a joint frailty survival model. 4. Recurrent bleeding endpoints as defined by a Consensus Report From the Bleeding Academic Research Consortium (doi: 10.1161/CIRCULATIONAHA.110.009449).	—

Measure

Time frame

1. Recurrent device-oriented weighted composite endpoints with endpoint definitions proposed by the Academic Research Consortium-2 Consensus Document. The weights of the individual endpoints will be predefined according to the Delphi panel of experts (doi:10.1093/eurheartj/ehu262). 2. Recurrent individual components of aforementioned composite endpoints: all-cause mortality, cardiovascular death, stroke (as defined by an academic research consortium initiative – doi:10.1093/eurheartj/ehx037), myocardial infarction, any revascularization, target lesion revascularization. These endpoint will be analyzed in a joint frailty survival model. 3. Recurrent effectiveness endpoints as a composite of any coronary revascularization (clinically driven) and any hospitalization either for a cardiac reason or related to the procedure with a joint frailty survival model. 4. Recurrent bleeding endpoints as defined by a Consensus Report From the Bleeding Academic Research Consortium (doi: 10.1161/CIRCULATIONAHA.110.009449).

—

Countries

Kazakhstan

Contacts

Public ContactAkhmetzhan Galimzhanov

Semey Medical University, Department of Cardiology and Interventional Arrhythmology

akhmetzhan.galimzhanov@nao-mus.kz8(7222)32-61-80

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 12, 2026